NVAX•benzinga•
Novavax Reports Smaller Q4 Loss, Shifts Focus From Commercializing COVID-19 Vaccine To Maximize Value
Summary
Novavax reported Q4 sales of $88.31 million, beating estimates despite a decline. The company shifts focus to partnerships and expects up to $350 million in 2025 revenue.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 27, 2025 by benzinga